HK1100358A1 - Gpr41 and modulators thereof for the treatment of insulin-related disorders gpr41 - Google Patents
Gpr41 and modulators thereof for the treatment of insulin-related disorders gpr41Info
- Publication number
- HK1100358A1 HK1100358A1 HK07108497.4A HK07108497A HK1100358A1 HK 1100358 A1 HK1100358 A1 HK 1100358A1 HK 07108497 A HK07108497 A HK 07108497A HK 1100358 A1 HK1100358 A1 HK 1100358A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- gpr41
- modulators
- insulin
- treatment
- related disorders
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62486704P | 2004-11-03 | 2004-11-03 | |
PCT/US2005/039551 WO2006052566A2 (fr) | 2004-11-03 | 2005-11-01 | Gpr41 et modulateurs de celui-ci utilises dans le traitement de troubles lies a l'insuline |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1100358A1 true HK1100358A1 (en) | 2007-09-21 |
Family
ID=36336982
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07108497.4A HK1100358A1 (en) | 2004-11-03 | 2007-08-06 | Gpr41 and modulators thereof for the treatment of insulin-related disorders gpr41 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20080312277A1 (fr) |
EP (1) | EP1812080B1 (fr) |
JP (2) | JP5785354B2 (fr) |
CN (1) | CN101084018B (fr) |
AU (1) | AU2005305083B2 (fr) |
CA (1) | CA2584224A1 (fr) |
ES (1) | ES2498972T3 (fr) |
HK (1) | HK1100358A1 (fr) |
IL (1) | IL182574A (fr) |
SG (1) | SG170642A1 (fr) |
TW (1) | TWI440460B (fr) |
WO (1) | WO2006052566A2 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA05007485A (es) | 2003-01-14 | 2006-01-30 | Arena Pharm Inc | Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia. |
AR045047A1 (es) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
AR045697A1 (es) | 2003-07-14 | 2005-11-09 | Arena Pharm Inc | Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo |
MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
CN102812011A (zh) | 2009-11-16 | 2012-12-05 | 梅利科技公司 | [1,5]-二氮杂环辛间四烯衍生物 |
JP5941916B2 (ja) | 2010-09-22 | 2016-06-29 | アリーナ ファーマシューティカルズ, インコーポレイテッド | Gpr119レセプターのモジュレーターおよびそれに関連する障害の処置 |
WO2014011926A1 (fr) | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comportant des statines, des biguanides et d'autres agents pour réduire un risque cardiométabolique |
JP6895378B2 (ja) | 2015-01-06 | 2021-06-30 | アリーナ ファーマシューティカルズ, インコーポレイテッド | S1p1受容体に関連する状態の処置方法 |
EP3939965A1 (fr) | 2015-06-22 | 2022-01-19 | Arena Pharmaceuticals, Inc. | Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique pour une utilisation dans des troubles associés au récepteur de s1p1 |
CN110520124A (zh) | 2017-02-16 | 2019-11-29 | 艾尼纳制药公司 | 用于治疗原发性胆汁性胆管炎的化合物和方法 |
TWI796596B (zh) | 2018-02-13 | 2023-03-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
CN112399874B (zh) | 2018-07-13 | 2024-03-22 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
CN112955435A (zh) | 2018-10-24 | 2021-06-11 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001232132A1 (en) * | 2000-02-18 | 2001-08-27 | Glaxo Group Limited | Novel assay |
EP1360199A2 (fr) * | 2001-02-16 | 2003-11-12 | Genentech, Inc. | Traitement faisant appel a dkk-1 ou aux antagonistes de dkk-1 |
EA200400011A1 (ru) * | 2001-06-07 | 2004-06-24 | Эли Лилли Энд Компани | Модуляторы рецепторов, активируемых пролифераторами пероксисом (prar) |
JP4294497B2 (ja) * | 2002-04-16 | 2009-07-15 | 協和発酵キリン株式会社 | 内分泌系細胞株とその利用法 |
US7553867B2 (en) * | 2002-09-06 | 2009-06-30 | Takeda Pharmaceutical Company Limited | Furan or thiophene derivative and medicinal use thereof |
WO2004038421A2 (fr) * | 2002-10-25 | 2004-05-06 | Bayer Healthcare Ag | Agents diagnostiques et therapeutiques pour maladies associees au recepteur 41 couple a une proteine g humaine (gpr41) |
-
2005
- 2005-11-01 SG SG200907252-1A patent/SG170642A1/en unknown
- 2005-11-01 EP EP05818064.7A patent/EP1812080B1/fr active Active
- 2005-11-01 ES ES05818064.7T patent/ES2498972T3/es active Active
- 2005-11-01 CA CA002584224A patent/CA2584224A1/fr not_active Withdrawn
- 2005-11-01 JP JP2007540382A patent/JP5785354B2/ja not_active Expired - Fee Related
- 2005-11-01 WO PCT/US2005/039551 patent/WO2006052566A2/fr active Application Filing
- 2005-11-01 AU AU2005305083A patent/AU2005305083B2/en not_active Ceased
- 2005-11-01 CN CN2005800370671A patent/CN101084018B/zh not_active Expired - Fee Related
- 2005-11-01 US US11/666,910 patent/US20080312277A1/en not_active Abandoned
- 2005-11-02 TW TW094138487A patent/TWI440460B/zh not_active IP Right Cessation
-
2007
- 2007-04-16 IL IL182574A patent/IL182574A/en not_active IP Right Cessation
- 2007-08-06 HK HK07108497.4A patent/HK1100358A1/xx not_active IP Right Cessation
-
2013
- 2013-02-01 JP JP2013018182A patent/JP2013082748A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ES2498972T3 (es) | 2014-09-26 |
CN101084018B (zh) | 2013-12-18 |
TWI440460B (zh) | 2014-06-11 |
SG170642A1 (en) | 2011-05-30 |
EP1812080A2 (fr) | 2007-08-01 |
JP2013082748A (ja) | 2013-05-09 |
WO2006052566A3 (fr) | 2006-10-12 |
WO2006052566A2 (fr) | 2006-05-18 |
JP2008518635A (ja) | 2008-06-05 |
EP1812080B1 (fr) | 2014-07-09 |
US20080312277A1 (en) | 2008-12-18 |
TW200633707A (en) | 2006-10-01 |
AU2005305083B2 (en) | 2012-02-02 |
JP5785354B2 (ja) | 2015-09-30 |
IL182574A0 (en) | 2008-04-13 |
CA2584224A1 (fr) | 2006-05-18 |
IL182574A (en) | 2014-04-30 |
CN101084018A (zh) | 2007-12-05 |
AU2005305083A1 (en) | 2006-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL182574A0 (en) | Gpr41 and modulators thereof for the treatment of insulin-related disorders | |
GB0404693D0 (en) | Pharmaceutical preparations for the treatment of ocular surface and other disorders | |
HK1190084A1 (zh) | 用於預防和治療補體相關紊亂的 多肽 | |
IL195819A0 (en) | Modulators of metabolism and the treatment of disorders related thereto | |
IL195851A0 (en) | Modulators of metabolism and the treatment of disorders related thereto | |
EP1926521A4 (fr) | Dispositifs et procedes pour liberer des substances therapeutiques pour le traitement de la sinusite et d'autres troubles | |
IL230241A (en) | Retinal history and methods of using them to treat visual irregularities | |
IL179227A0 (en) | Methods and reagents for the treatment of immunoinflammatory disorders | |
IL188204A0 (en) | Combination therapy for the treatment of immunoinflammatory disorders | |
IL178775A (en) | Pharmaceuticals containing glucocorticoid for use in the treatment of disorders requiring acute glucocorticoid therapy | |
PL378108A1 (pl) | Leczenie łączone do terapii zapalnych zaburzeń immunologicznych | |
ZA200705540B (en) | Compositions comprising PDE4 modulators and their use for the treatment or prevention of airway inflammation | |
IL181706A0 (en) | The treatment of inflammatory disorders and pain | |
PL2982372T3 (pl) | Środki modulujące stężenie glutaminianu stosowane w leczeniu zaburzeń psychicznych | |
EP1812077A4 (fr) | Modulateurs de epha2 et de ephrina1 pour traiter une maladie associee a la fibrose | |
IL183656A0 (en) | Indenyl derivatives and use thereof for the treatment of neurological disorders | |
EP1814567A4 (fr) | Utilisation de modulateurs de epha2 et de ephrina1 pour traiter et la prevenir des infections | |
IL178827A0 (en) | Use of reboxetine for the treatment of pain | |
ZA200705083B (en) | Use of a 5-HT6 agonist for the treatment and prevention of neurodegenerative disorders | |
IL198134A (en) | A combination of antipsychotic drugs and tetracyclines to treat psychiatric illnesses | |
IL181777A0 (en) | Gpr43 and modulators thereof for the treatment of metabolic-related disorders | |
EP1812009A4 (fr) | Antagonistes des steroides gaba et leur utilisation dans le traitement des troubles du snc | |
ZA200505996B (en) | Combination therapy for the treatment of immunoinflammatory disorders | |
GB0419828D0 (en) | The treatment of inflammatroy disorders and pain | |
ZA200704412B (en) | Indenyl derivatives and use thereof for the treatment of neurological disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20181101 |